Microbiotica
Hinxton
Cambridge
United Kingdom
About Microbiotica
Microbiotica, a new company from the Wellcome Trust Sanger Institute and focuses on human microbiome.YEAR FOUNDED:
2016
23 articles about Microbiotica
-
Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma
4/12/2023
Microbiotica today announces it has entered into a clinical trial collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA).
-
Microbiotica Announces Transition of Leadership
11/29/2022
Microbiotica announces a change of leadership as Mike Romanos hands over the Microbiotica CEO role to current COO, Tim Sharpington.
-
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
-
Microbiotica Raises £50m ($67m) to Advance Pipeline of Microbiome-based Therapeutics
3/7/2022
Microbiotica today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.
-
Microbiotica’s Live Bacterial Therapeutic, MB097, in development to begin clinical trials in 2022 in immuno-oncology
6/23/2021
Microbiotica today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022.
-
Microbiotica, Cancer Research UK and Cambridge University Hospitals Collaborate in Landmark Cancer Microbiome Study
6/8/2020
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust, announce a collaboration to identify and develop microbiome co-therapeutics and biomarkers for cancer patients receiving immune checkpoint inhibitor therapy.
-
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman
9/25/2019
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.
-
Microbiotica Presenting at Key Microbiome Events in Q1 2019
1/28/2019
Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference activity for the first quarter of 2019.
-
Microbiotica Wins Life Sciences Company of the Year at Cambridge Independent Awards
11/2/2018
Microbiotica announces that it has been named Life Sciences Company of the Year at the Cambridge Independent Awards, which took place last night at the Hilton Cambridge City Centre Hotel.
-
Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®
10/30/2018
Microbiotica today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7 November.
-
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund
10/24/2018
Seventure Partners, a specialist investor in the microbiome, commits new funding fromHealth for Life Capital™ and strengthens Microbiotica’s Board with microbiome sector expertise and know-how
-
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
-
Microbiotica Collaborates with University of Adelaide to Develop a Novel Microbial Therapy for Ulcerative Colitis
6/19/2018
Microbiotica, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC).
-
Microbiotica Enters into Microbiome Collaboration with Genentech
6/6/2018
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline
-
Genentech, a Roche company, and Microbiotica signed a multi-year strategic collaboration to discover, develop and commercialize biomarkers, targets and drugs for inflammatory bowel disease (IBD).
-
Microbiotica to Present at Top Microbiome Conferences
5/22/2018
Microbiotica announces that it will present at leading microbiome conferences throughout May and June.
-
Microbiotica to Participate in Microbiome Panel at BIO-Europe
10/25/2017
Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe, which will be held from 6-8 November, in Berlin, Germany.
-
Microbiotica Celebrates Successful First Year With Third Award Win
10/11/2017
-
Microbiotica Wins Biotech And Money’s "Life Science Spin-Out Of The Year"
9/18/2017
-
Microbiotica To Present At Leading Microbiome Summit
9/18/2017